Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Richards, H.

Search results

  • RSS Feed
(1 - 8 of 8)
Secukinumab improves active psoriatic arthritis and inhibits radiographic progression: Results of a phase 3 randomized, multicenter, double-blind, placebo-controlled study
Mease, P.; McInnes, I.B.; Kirkham, B.; Kavanaugh, A.; Rahman, P.; Heijde, D. van der; ... ; Mpofu, S. 2015
Secukinumab improves active psoriatic arthritis and inhibits radiographic progression: Results of a phase 3 randomized, multicenter, double-blind, placebo-controlled study
Article / Letter to editor
metadata only
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
McInnes, I.B.; Mease, P.J.; Kirkham, B.; Kavanaugh, A.; Ritchlin, C.T.; Rahman, P.; ... ; FUTURE 2 Study Grp 2015
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
Article / Letter to editor
metadata only
SECUKINUMAB, A HUMAN ANTI-INTERLEUKIN-17A MONOCLONAL ANTIBODY, IMPROVES ACTIVE PSORIATIC ARTHRITIS AND INHIBITS RADIOGRAPHIC PROGRESSION: EFFICACY AND SAFETY DATA FROM A PHASE 3 RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Nash, P.; Mease, P.; McInnes, I.; Kirkham, B.; Kavanaugh, A.; Rahman, P.; ... ; Mpofu, S. 2015
SECUKINUMAB, A HUMAN ANTI-INTERLEUKIN-17A MONOCLONAL ANTIBODY, IMPROVES ACTIVE PSORIATIC ARTHRITIS AND INHIBITS RADIOGRAPHIC PROGRESSION: EFFICACY AND SAFETY DATA FROM A PHASE 3 RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Article / Letter to editor
metadata only
SECUKINUMAB, A MONOCLONAL ANTIBODY TO INTERLEUKIN-17A, PROVIDES SIGNIFICANT AND SUSTAINED INHIBITION OF JOINT STRUCTURAL DAMAGE IN ACTIVE PSORIATIC ARTHRITIS REGARDLESS OF PRIOR TNF INHIBITORS OR CONCOMITANT METHOTREXATE: A PHASE 3 RANDOMIZED, DOUBLE-BLIN
Collins, A.; Heijde, D. van der; Landewe, R.; Mease, P.; McInnes, I.; Conaghan, P.; ... ; Mpofu, S. 2015
SECUKINUMAB, A MONOCLONAL ANTIBODY TO INTERLEUKIN-17A, PROVIDES SIGNIFICANT AND SUSTAINED INHIBITION OF JOINT STRUCTURAL DAMAGE IN ACTIVE PSORIATIC ARTHRITIS REGARDLESS OF PRIOR TNF INHIBITORS OR CONCOMITANT METHOTREXATE: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Article / Letter to editor
metadata only
SECUKINUMAB, A HUMAN ANTI-INTERLEUKIN-17A MONOCLONAL ANTIBODY, IMPROVES ACTIVE PSORIATIC ARTHRITIS AND INHIBITS RADIOGRAPHIC PROGRESSION: EFFICACY AND SAFETY DATA FROM A PHASE 3 RANDOMIZED, MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Tahir, H.; Mease, P.; McInnes, I.B.; Kirkham, B.; Kavanaugh, A.; Rahman, P.; ... ; Mpofu, S. 2015
SECUKINUMAB, A HUMAN ANTI-INTERLEUKIN-17A MONOCLONAL ANTIBODY, IMPROVES ACTIVE PSORIATIC ARTHRITIS AND INHIBITS RADIOGRAPHIC PROGRESSION: EFFICACY AND SAFETY DATA FROM A PHASE 3 RANDOMIZED, MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Article / Letter to editor
metadata only
Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis: 24-Week Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using Subcutaneous Dosing
McInnes, I.B.; Mease, P.J.; Kirkham, B.; Kavanaugh, A.; Ritchlin, C.T.; Rahman, P.; ... ; Mpofu, S. 2014
Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis: 24-Week Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using Subcutaneous Dosing
Article / Letter to editor
metadata only
Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study
Mease, P.; McInnes, I.B.; Kirkham, B.; Kavanaugh, A.; Rahman, P.; Heijde, D. van der; ... ; Mpofu, S. 2014
Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study
Article / Letter to editor
metadata only
Secukinumab, a Monoclonal Antibody to Interleukin-17A, Provides Significant and Sustained Inhibition of Joint Structural Damage in Active Psoriatic Arthritis Regardless of Prior TNF Inhibitors or Concomitant Methotrexate: A Phase 3 Randomized, Double-Blin
Heijde, D. van der; Landewe, R.B.M.; Mease, P.; McInnes, I.B.; Conaghan, P.G.; Pricop, L.; ... ; Mpofu, S. 2014
Secukinumab, a Monoclonal Antibody to Interleukin-17A, Provides Significant and Sustained Inhibition of Joint Structural Damage in Active Psoriatic Arthritis Regardless of Prior TNF Inhibitors or Concomitant Methotrexate: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
Article / Letter to editor
metadata only